Abstract 130P
Background
In carcinoma esophagus patients where large volumes of lymphocyte producing organs and organs with circulating lymphocytes are exposed to radiation field, Radiation induced lymphopenia (RIL) is quite profound. Absolute Lymphocyte Count (ALC) has been postulated to have a crucial impact on treatment outcomes.In this study, dosimetric analysis on the organs at risk (OARs) for lymphopenia and its effect on pathological complete response (PCR) was assessed.
Methods
Carcinoma Esophagus patients who underwent neoadjuvant chemo-radiotherapy(NACT-RT) and definitive surgery from December 2018 to March 2021 were studied retrospectively. Data collected included baseline and weekly ALC, PCR on histopathology, mean dose (Dmean) and volume based dosimetry of the OARs for lymphopenia (thoracic vertebrae, bilateral lungs, liver, heart and spleen) and the effective dose to the circulating lymphocytes (EDIC), calculated using the formulae 0.12 (Dmean lung) + 0.08 (Dmean heart) + [0.45+ 0.35x 0.85(no of fractions/45ˆ1/2] Dmean body. PCR rates were correlated with ALC using Spearman’s correlation. Dosimetric parameters and EDIC was correlated with ALC using Pearson’s correlation test (p value<0.05).
Results
33 patient’s data who were eligible for the study was analysed. On Pearson’s correlation test the thoracic vertebrae Dmean (p-0.008) and V15 (p-0.012), liver Dmean (p-0.034) and V20 (p-0.038), heart Dmean (p-0.013) and V15 (p-0.022), spleen Dmean (p-0.040) were found to have significant correlation with ALC nadir. The mean EDIC was 6.21 (SD±5). No significant correlation between EDIC and ALC nadir was identified. 5% of patients did not achieve PCR at surgery. Spearman’s correlation test did not show a significant correlation between PCR and ALC nadir.
Conclusions
RIL has been demonstrated to have a negative impact on treatment outcomes. In our study, we discovered that dosimetric parameters of Dmean and volume based analysis of the OARs for lymphopenia were strongly correlated with ALC Nadir. Statistically significant correlation between ALC nadir and PCR rates was not seen. A larger multicentric study with a large number of patients, however, may be required to statistically prove our hypothesis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
128P - Survival outcome of gastric cancer patients in a tertiary care center: A 10-year single center retrospective study
Presenter: Dawn Lynn Guardiario
Session: Poster viewing 02
129P - Chemoradiation in carcinoma esophagus with weekly paclitaxel ad carboplatin: A real-world experience from a tertiary care center
Presenter: Nidhi Sharma
Session: Poster viewing 02
131TiP - ASCEND: Randomized, double-blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in untreated metastatic pancreatic ductal adenocarcinoma - An Australasian Gastro-Intestinal Trials Group (AGITG) trial ACTRN12621001290886
Presenter: Andrew Dean
Session: Poster viewing 02
134TiP - A phase I/II study of nanoliposomal irinotecan plus S-1 in metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy
Presenter: Hiroshi Imaoka
Session: Poster viewing 02